Expertise in
13
conditions

Xavier Montalban

St, 
Toronto, ON, CA 
Expertise in
13
conditions
St, 
Toronto, ON, CA 

Overview

Xavier Montalban practices in Toronto, Canada. Mr. Montalban is highly rated in 13 conditions, according to our data. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Optic Neuritis.

His clinical research consists of co-authoring 578 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Male

Locations

St, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study
Enrollment Status: Terminated
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 3
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques
Enrollment Status: Completed
Publish Date: August 25, 2020
Intervention Type: Procedure
View 2 Less Clinical Trials

578 Total Publications

A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study.
Journal: Neurodegenerative disease management
Published: April 07, 2026

Frequently Asked Questions about Xavier Montalban

Is Xavier Montalban a top-rated expert for Multiple Sclerosis (MS)?

MediFind is an objective health platform that identifies experts based on real-world data. Xavier Montalban is classified as an Elite expert for Multiple Sclerosis (MS), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Xavier Montalban participate in research or clinical trials?

Yes. Xavier Montalban has published 578 articles and abstracts on conditions like Multiple Sclerosis (MS). You can view a list of Xavier Montalban's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Montalban's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 34 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile